Table 1.
Summary of the Isolated HIV-1 bNAbs and Env-Specific mAbs for Isotype, Genetic Composition, Epitope, and Neutralization Characteristics
| mAb ID | Donor | Isotype | V-gene∗(hypermutation) | CDR3 length(amino acid) | Epitope | Neutralization |
|---|---|---|---|---|---|---|
| M4008_N1 | M4008 | IgG2 (IgA) | VH1-69 (28%) VK1-5 (24%) | H3: 17, L3: 9 | V3 loop | tier-2 (B), 38% breadth |
| M4008_N2 | M4008 | IgG3 | VH4-61 (28%) VL3-21 (11%) | H3: 15, L3: 11 | Env trimer or gp41 | tier-2, weak potency |
| M4008_b3 | M4008 | IgG1 | VH3-30 (14%) VL1-47 (15%) | H3: 20, L3: 11 | gp120, CD4bs∗ | tier-1 |
| M4008_b3.2 | M4008 | IgG1 | VH3-30 (19%) VL1-47 (12%) | H3: 20, L3: 11 | gp120, CD4bs | tier-1 |
| M4008_b4 | M4008 | IgG1 | VH1-18 (16%) VK3-20 (12%) | H3: 21, L3: 9 | gp120, CD4bs | tier-1 |
| M4008_b5 | M4008 | IgG1 | VH4-34 (13%) VK4-1 (3%) | H3: 23, L3: 10 | gp120, V3 tip | tier-1 |
| M4008_b6 | M4008 | IgG1 | VH1-69-2 (15%) VK1-39 (12%) | H3: 14, L3: 9 | gp120, V3 tip | tier-1 |
| M4008_b7 | M4008 | IgG3 | VH3-30 (15%) VK2-28 (15%) | H3: 17, L3: 10 | gp41 | None |
| M1214_N1 | M1214 | IgG1 (IgA) | VH3-66 (35%) VL2-11 (24%) | H3: 18, L3: 11 | V2V5 corridor | tier-2, 57% breadth |
| M1214_N2 | M1214 | IgG1 | VH4-34 (30%) VK2-24 (17%) | H3: 11, L3: 9 | V3 glycans | tier-2 (B), 26% breadth |
| M1214_N2.2 | M1214 | IgG1 | VH4-34 (27%) VK2-24 (20%) | H3: 11, L3: 9 | V3 glycans | tier-2 (B), 20% breadth |
| M1214_N3 | M1214 | IgG1 | VH6-1 (24%) VL1-44 (20%) | H3: 19, L3: 11 | V3 glycans | tier-2, partial neutralization |
| M1214_b4 | M1214 | IgG1 | VH1-69 (26%) VK3-20 (20%) | H3: 15, L3: 8 | gp41 | None |
An ∗ indicates the mAb sequences were assigned to the closest known human germline V-genes as appropriate; Abbreviation is as follows: CD4bs, CD4-binding site.